Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Bourla and Afeyan said they began talking about this new approach in the depths of the pandemic, when they were “partners-slash-competitors,” as Bourla puts it, in the effort to create a vaccine.

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat ...

A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public. The ...